Acorda Named One of the Best Workplaces by Fortune Magazine and Great Place to Work
October 12 2016 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of
the 100 Best Medium Workplaces based on an independent survey
by Fortune Magazine and Great Place to Work®.
The survey included more than 52,000 employees at over 450
companies based in the United States. Companies included on
the list showed strong corporate culture, a commitment to employee
benefits, a deep engagement among employees, and a clear sense of
mission.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161012005439/en/
Acorda Therapeutics, Inc. has been named
as one of the 100 Best Medium Workplaces based on an independent
survey by Fortune Magazine and Great Place to Work®. (Photo:
Business Wire)
“We’re gratified to receive this recognition. Our associates
have established a culture that values trust, collaboration and
open communication. This culture is an extension of our mission to
develop therapies that improve the lives of people with
neurological disorders,” said Ron Cohen, M.D., Acorda's
President and CEO. “Developing new, life-changing medicines is an
incredibly challenging undertaking, which our associates embrace.
Being able to come to work with like-minded individuals, in a
supportive, rewarding and fun environment, helps us to stay focused
on that mission.”
In addition to being named one of the Best Medium Workplaces,
Acorda was also recognized by Fortune and Great Place to Work in
2016 as one of the Best Workplaces for Women (second year in a
row), as well as Best Workplaces for Baby Boomers and Best
Workplaces for Millennials. The Company has also been recognized as
one of the Best Places to Work in New York for six consecutive
years by the Best Companies Group, ranking 3rd in 2016
among employers with more than 250 associates. These recognitions
highlight Acorda’s commitment to creating an inclusive and diverse
workplace that values the contributions of all associates.
The Best Medium Workplaces list was determined by surveying
employees on factors such as their feelings on management’s
credibility, the degree of support for employees' personal and
professional lives, employees’ overall job satisfaction, and sense
of camaraderie. Fortune and Great Place to Work also assessed
corporate culture, salary and benefit programs, hiring practices,
internal communication, training, recognition programs, and
diversity efforts in determining the final rankings.
For more information on careers at Acorda, please visit
http://www.acorda.com/careers.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda has an industry leading pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s
disease, post-stroke walking difficulties, migraine, and multiple
sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of
unfavorable results from future studies of Ampyra or from our other
research and development programs, including CVT-301 or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, any other products under development, or the
products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our
products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of
the U.S. and our dependence on our collaborator Biogen in
connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this presentation are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this presentation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161012005439/en/
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2024 to May 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From May 2023 to May 2024